title: Incidence of Intraocular Pressure Elevation following Intravitreal Ranibizumab (Lucentis) for Age-related Macular Degeneration.
abstract: OBJECTIVE
  The aim of this article is to evaluate the rate of patients developing sustained elevated intraocular pressure (IOP) after ranibizumab (Lucentis) intravitreal (IVT) injections.
  
  
  METHODS
  This is a retrospective study.
  
  
  METHODS
  Charts of 192 consecutive patients receiving Lucentis for age-related macular degeneration (AMD) were retrospectively reviewed.
  
  
  METHODS
  We enrolled patients with at least two IOP measurements between injections. Elevated IOP was defined as >21 mm Hg with an increase of at least 20% from baseline. Noninjected contralateral eyes of the same patient cohort were used as control.
  
  
  METHODS
  Primary outcome was defined as elevated IOP. Secondary outcomes were presence and type of glaucoma, number of injections, and time to IOP elevation.
  
  
  RESULTS
  Elevated IOP occurred at a significantly higher rate in eyes receiving IVT ranibizumab (7.47%; n = 9) compared with control (0.93%; n = 1). Patients with preexisting glaucoma or ocular hypertension (OHT) were more likely to develop elevated IOP after IVT ranibizumab injection.
  
  
  CONCLUSIONS
  Intravitreal ranibizumab injections are associated with sustained IOP elevation in some eyes.
  Reis GMSM, Grigg J, Chua B, Lee A, Lim R, Higgins R, Martins A, Goldberg I, Clement CI. The Incidence of Intraocular Pressure Elevation following Intravitreal Ranibizumab (Lucentis) for Age-related Macular Degeneration. J Curr Glaucoma Pract 2017;11(1):3-7.
authors.affiliation: Consultant, Glaucoma Unit, Sydney Eye Hospital, Sydney, New South Wales, Australia.
authors.forename: Gustavo Msm
authors.initials: GM
authors.lastname: Reis
authors.affiliation: Associate Professor, Glaucoma Unit, Sydney Eye Hospital, Sydney; Discipline of Ophthalmology, Central Clinical School, University of Sydney Sydney, New South Wales, Australia.
authors.forename: John
authors.initials: J
authors.lastname: Grigg
authors.affiliation: Clinical Lecturer and Staff Specialist, Glaucoma Unit, Sydney Eye Hospital, Sydney; Discipline of Ophthalmology, Central Clinical School, University of Sydney Sydney, New South Wales, Australia.
authors.forename: Brian
authors.initials: B
authors.lastname: Chua
authors.affiliation: Clinical Lecturer and Staff Specialist, Glaucoma Unit, Sydney Eye Hospital, Sydney; Discipline of Ophthalmology, Central Clinical School, University of Sydney Sydney, New South Wales, Australia.
authors.forename: Anne
authors.initials: A
authors.lastname: Lee
authors.affiliation: Clinical Lecturer and Visiting Medical OfficerGlaucoma Unit, Sydney Eye Hospital, Sydney; Discipline of Ophthalmology, Central Clinical School, University of Sydney Sydney, New South Wales, Australia.
authors.forename: Ridia
authors.initials: R
authors.lastname: Lim
authors.affiliation: Visiting Medical Officer, Glaucoma Unit, Sydney Eye Hospital, Sydney; Discipline of Ophthalmology, Central Clinical School, University of Sydney Sydney, New South Wales, Australia.
authors.forename: Ralph
authors.initials: R
authors.lastname: Higgins
authors.affiliation: Consultant, Department of Ophthalmology, Moorfields Eye Hospital London, United Kingdom.
authors.forename: Alessandra
authors.initials: A
authors.lastname: Martins
authors.affiliation: Clinical Associate Professor, Glaucoma Unit, Sydney Eye Hospital, Sydney; Discipline of Ophthalmology, Central Clinical School, University of Sydney Sydney, New South Wales, Australia.
authors.forename: Ivan
authors.initials: I
authors.lastname: Goldberg
authors.affiliation: Clinical Lecturer and Staff Specialist, Glaucoma Unit, Sydney Eye Hospital, Sydney; Discipline of Ophthalmology, Central Clinical School, University of Sydney Sydney, New South Wales, Australia.
authors.forename: Colin I
authors.initials: CI
authors.lastname: Clement
keywords: Age-related macular degeneration; Intraocular pressure; Ranibizumab.